AbbVie and Galapagos present cystic fibrosis corrector and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AbbVie and Galapagos present cystic fibrosis corrector and potentiator screening approach at ECFS conference

MECHELEN, Belgium, June 15, 2015 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announced a joint presentation with AbbVie (NYSE: ABBV ) at the 38 th annual European Cystic Fibrosis Society conference in Brussels, Belgium.

"Development of Trafficking Assays to Evaluate Novel Corrector-Potentiator Combinations,"   presented by Dr Corina Balut of AbbVie, disclosed for the first time new assays developed by Galapagos and AbbVie to evaluate the impact of corrector molecules on  the rescue of CFTR-F508del and to gain insight into the influence of each component in combination cocktails.   Among these was the combination of AVI-tagged CFTR with an MSD discovery platform to provide a more specific and sensitive approach in studying the endocytosis and degradation rate of plasma membrane CFTR.  This particular new assay also characterizes the effect of various correctors on channel stability at the cell surface and its endocytosis/recycling, allowing for a better understanding of the mechanism of action of compounds.

The presentation is available for download on the Galapagos website.

Galapagos and AbbVie are working together to develop a triple combination therapy for cystic fibrosis patients with the Class II (F508del) mutation.  Novel potentiator GLPG1837 is currently in Phase 1 and is expected to enter a Phase 2 study in class III mutation patients before end 2015.   Novel corrector GLPG2222 is expected to enter Phase 1 before end 2015.  Galapagos and AbbVie expect to nominate a second novel corrector by Q3 2015 and thereby complete the triple combination therapy discovery phase.  This second novel corrector is expected to enter Phase 1 in Q2 2016.

About Galapagos Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications.  In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib .  Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease. Galapagos reported good activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2 trials in RA.  AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene.  Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage.  GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.  GLPG1690 , a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis.  The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  More info at www.glpg.com

CONTACT

Galapagos NV Elizabeth Goodwin, Head of Corporate Communications & IR Tel: +31 6 2291 6240 ir@glpg.com

Galapagos forward-looking statements This release may contain forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," "continues," "we believe," "we intend," as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements and estimating the commercial potential of our product candidates.  A further list and description of these risks, uncertainties and other risks can be found in the company's Securities and Exchange Commission filing and reports, including in the company's prospectus filed with the SEC on May 14, 2015 and future filings and reports by the company. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

HUG#1928322

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 6

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 32

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 58

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 0

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 89

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 23

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 217

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 81

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

DoubleLine Income Solutions Fund Announces Monthly Distribution

Updated Category News Views 43

Back when the DoubleLine Income Solutions Fund made its rounds with a $0.11 per share distribution, traders were left scratching their heads over what it really meant for income stability. Sure, on paper it looked like a win—monthly distributions usually signal healthy cash flow—but the devil's in the details. The $0.11 Question: Solid Distribution or Just Smoke? That...

Continue Reading
Antiarrhythmic Drugs Market Growth and Future Projections

Updated Category News Views 115

Understanding the Future of the Antiarrhythmic Drugs Market The global antiarrhythmic drugs market is on a promising trajectory, with forecasts indicating a significant rise from USD 1.02 billion in 2023 to a remarkable USD 1.77 billion by 2032. This growth represents a compounded annual growth rate (CAGR) of 6.30% from 2024 to 2032. Increasing Demand Driven by Rising...

Continue Reading
Alvarez & Marsal Capital Partners Joins Forces with East Coast Power for Growth

Updated Category News Views 539

Alvarez & Marsal Capital Partners Forms Strategic Alliance Alvarez & Marsal Capital Partners has announced a pivotal strategic partnership with East Coast Power, marking an essential move to boost the development of electric utility services. This collaboration promises to provide the necessary investment aimed at accelerating East Coast Power's growth, with a clear focus...

Continue Reading
Sinclair Media Invites Applications for 2025 Diversity Scholarship

Updated Category News Views 126

Sinclair Announces Diversity Scholarship Program for Students Sinclair has exciting news — the company's annual Diversity Scholarship program is officially open for submissions for the upcoming academic year. This initiative has contributed nearly $400,000 to support students pursuing their education since it began in 2013. Empowering Diverse Voices in Broadcasting The...

Continue Reading
Traveling in Comfort: King's Hawaiian Unveils Softwear Line

Updated Category News Views 111

Experience Unmatched Comfort with King’s Hawaiian Softwear In an exciting new initiative, King’s Hawaiian invites travelers to embrace total comfort with their latest collection: the Softwear line. Designed to echo the signature fluffiness of the brand's beloved dinner rolls, these ultra-soft sweatshirts and sweatpants provide a perfect blend of comfort and style....

Continue Reading